Growth Contrast Tool

Overview

The growth contrast tool is intended to help ICBs identify important local effects on prescribing costs. The figures are derived by comparing growth in prescribing costs and items in selected SICBLs with what might have happened if national growth patterns had applied. Comparing actual growth with counterfactuals based on national growth patterns should remove the effect of system-wide changes (e.g. price increases, patent expiries, discontinuations, shortages, implementation of national guidance, etc.) & bring local effects into focus.

Data Period

April 2023 to March 2024

Frequency

Quarterly

Teriparatide for treatment of osteoporosis in men aged over 50 years

Overview

Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.

The aim of this evaluation report is to review the evidence for the efficacy, safety, and tolerability of teriparatide for use in male patients for osteoporosis treatment.

Social Prescribing: Evidence and Outcomes

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.

Social prescribing has been proposed as a mechanism to improve the health of populations while reducing or avoiding pharmacological treatment, thereby reducing overprescribing. This report provides an overview of the evidence for the effectiveness of social prescribing and evaluates the impact of a large social prescribing scheme on primary care prescribing of medicines.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Optimised prescribing of oral iron supplements for iron deficiency anaemia

Overview

Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.

Iron deficiency anaemia (IDA) is estimated to affect 3% of men and 8% of women in the UK. Treatment involves addressing the underlying cause, and replenishing iron stores through iron replacement therapy. This document aims to outline the updated recommendations on dosing of oral iron supplements for IDA and their basis. It w also includes advice on monitoring treatment response and duration of treatment and highlights the potential benefits of implementing the latest guidelines.

Prescribing Update Newsletter – March 2024

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on recent RDTC publications and the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources.

View the preview below on desktop, or click here to download a copy

Monthly formulary amendments – March 2024

Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines.  This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.

This edition covers guidance and alerts published in March 2024.

It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Updated 1st May 2024 to correct a typographical error.

Shared care protocol – lithium in adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.0

Last updated: 22nd March 2024

Formulary assessment – Levomepromazine (Levorol) 6.25mg tablets

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

This publication was updated in April 2024 to reflect the licensing of an oral solution for the treatment of refractory nausea unassociated with chemotherapy.

Monthly Horizon Scanning Report – March 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Shared care protocol – sulfasalazine in adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.0

Last updated: 8th March 2024